<DOC>
	<DOCNO>NCT00226421</DOCNO>
	<brief_summary>The purpose study evaluate analgesic efficacy safety oxymorphone extend release opioid-experienced patient chronic low back pain .</brief_summary>
	<brief_title>Efficacy Safety Oxymorphone Extended Release Opioid-Experienced Patients With Chronic Non-Malignant Pain</brief_title>
	<detailed_description>Patients chronic low back pain stable opioid treatment convert oxymorphone extend release ( ER ) enter open-label treatment phase.During Open-Label Titration Period ( 28 day ) , patient receive daily oxymorphone ER PO q12h . Patients stabilize dose provide adequate pain relief randomize either continue stabilize dose oxymorphone ER receive placebo double-blind fashion total duration 12 week .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>Males females 18 year age older In good health determine Investigator basis medical history physical examination . Moderate severe chronic nonneuropathic low back pain present daily least several hour per day minimum three month prior screen . On stable aroundtheclock opioid pain medication management moderate severe chronic lower back pain . Expected require total daily oxymorphone ER dose minimum 20 mg per day ( oral morphine equivalent : approximately 60 mg ) exceed 220 mg oxymorphone ER ( oral morphine requirement : approximately 660 mg ) . Any adjunct therapy back pain physical therapy , biofeedback therapy , acupuncture therapy herbal remedy , base patient 's current status remain unchanged period participation patient . Written inform consent Pregnant and/or lactate Subjects radiculopathy , fibromyalgia , reflex sympathetic dystrophy causalgia ( complex regional pain syndrome ) , acute spinal cord compression , cauda equina compression , acute nerve root compression , severe low extremity weakness numbness , bowel bladder dysfunction secondary cauda equina compression , diabetic amyotrophy , meningitis , discitis , back pain due secondary infection tumor . Can agree stop local regional pain treatment study ( nerve/plexus block ablation , neurosurgical procedure pain control , Botulinum toxin injection , inhalation analgesia ) . The patient must nerve/plexus block within 4 week screen ( Visit 1 ) . The patient must Botulinum toxin injection lower back region within 3 month screen . Intend alter physical therapy regimen study . Surgical procedure direct towards source back pain within 6 month screen . Pain secondary confirm suspected neoplasm . Dysphagia difficulty swallow tablet capsule . Significant prior history substance abuse alcohol abuse . Use investigational medication within 30 day prior first dose study medication . Previous exposure oxymorphone . History clinically significant intolerance oxymorphone know hypersensitivity opioid analgesic . History seizure . use MAO inhibitor within 14 day prior start study medication . Other clinically significant condition judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>opioid</keyword>
	<keyword>oxymorphone</keyword>
	<keyword>chronic pain</keyword>
	<keyword>randomize , double-blind trial</keyword>
	<keyword>low back pain</keyword>
</DOC>